The U.K.'s cost-effectiveness watchdogs gave a thumbs up to Gilead Sciences' ($GILD) combo hepatitis C pill Harvoni, despite its £39,000 price, or about $58,000. The pill combines Gilead's new blockbuster hep C drug Sovaldi with another antiviral, ledipasvir, and has delivered impressive cure rates. The drug costs significantly more in the U.S., where its list price is $94,500. Report